Role of Glutamate-mediated Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme

What this Trial Is About

Gliomas are the most common primary brain tumors in adults, with glioblastoma multiforme (GBM) being the most aggressive and associated with the poorest outcomes. Researchers are studying the role of glutamate, an amino acid important for brain function, in GBM growth and invasion. Alterations in glutamate synthesis and signaling may influence tumor aggressiveness, making it a focus for potential new treatments. The study involves measuring levels of glutamate and related proteins in blood, cerebrospinal fluid (CSF), and tumor tissue from adult patients with brain lesions suspected to be GBM. These patients are candidates for complete tumor removal surgery followed by radiotherapy and chemotherapy. Samples will be collected at baseline before surgery and during follow-up visits at 3, 6, and 9 months. Molecular analyses and imaging, including MRI scans, will also be performed. Participants will undergo regular blood sampling and MRI scans at specified intervals to monitor glutamate levels and tumor progression. Researchers will assess changes in glutamate and its scavengers in serum and CSF over time to understand their relationship with disease activity. The study includes collection of clinical and imaging data throughout the follow-up period, with the total observation lasting at least 9 months after surgery.

Glutamate Excitotoxicity and Its Role in Glioblastoma Biology